J
Jeremy A. Squire
Researcher at University of São Paulo
Publications - 349
Citations - 41173
Jeremy A. Squire is an academic researcher from University of São Paulo. The author has contributed to research in topics: Comparative genomic hybridization & Fluorescence in situ hybridization. The author has an hindex of 87, co-authored 344 publications receiving 38764 citations. Previous affiliations of Jeremy A. Squire include University of Toronto & Kingston General Hospital.
Papers
More filters
Journal ArticleDOI
Single cell-derived clonal analysis of human glioblastoma links functional and genomic heterogeneity.
Mona Meyer,Jüri Reimand,Xiaoyang Lan,Renee Head,Xueming Zhu,Michelle Kushida,Jane Bayani,Jessica C. Pressey,Anath C. Lionel,Ian D. Clarke,Michael D. Cusimano,Jeremy A. Squire,Stephen W. Scherer,Mark Bernstein,Melanie A. Woodin,Gary D. Bader,Peter B. Dirks +16 more
TL;DR: It is predicted that integration of functional and genomic analysis at a clonal level will be essential for understanding evolution and therapeutic resistance of human cancer, and will lead to the discovery of novel driver mechanisms and clone-specific cancer treatment.
Journal ArticleDOI
Discordant KCNQ1OT1 imprinting in sets of monozygotic twins discordant for Beckwith–Wiedemann syndrome
Rosanna Weksberg,Cheryl Shuman,Oana Caluseriu,Adam C. Smith,Yan-Ling Fei,Joy L. Nishikawa,Tracy Stockley,Lyle Best,David Chitayat,Ann Haskins Olney,Elizabeth Ives,Adele Schneider,Timothy H. Bestor,Madeline Li,Paul D. Sadowski,Jeremy A. Squire +15 more
TL;DR: It is shown here that the incidence of female monozygotic twins among patients with BWS is dramatically increased over that of the general population, and that KCNQ1OT1 is especially vulnerable to a loss of imprinting event at a critical stage of preimplantation development.
Journal ArticleDOI
Immortal human pancreatic duct epithelial cell lines with near normal genotype and phenotype
Hong Ouyang,Lun-jun Mou,Catherine Luk,Ni Liu,Jana Karaskova,Jeremy A. Squire,Jeremy A. Squire,Ming-Sound Tsao,Ming-Sound Tsao +8 more
TL;DR: Results indicate that except for the loss of p53 functional pathway, the two clones of HPDE6-E6E7 cells demonstrated a near normal genotype and phenotype of pancreatic duct epithelial cells, which will be useful for future studies on the molecular basis of pancreas cancerogenesis and islet cell differentiation.
Journal ArticleDOI
Tumour genomic and microenvironmental heterogeneity for integrated prediction of 5-year biochemical recurrence of prostate cancer: a retrospective cohort study
Emilie Lalonde,Emilie Lalonde,Adrian Ishkanian,Jenna Sykes,Michael Fraser,Michael Fraser,Helen Ross-Adams,Nicholas Erho,Mark J Dunning,Silvia Halim,Alastair D. Lamb,Nathalie C. Moon,Gaetano Zafarana,Gaetano Zafarana,Anne Y. Warren,Xianyue Meng,John Thoms,John Thoms,Michal R. Grzadkowski,Alejandro Berlin,Alejandro Berlin,Cherry Have,Varune Rohan Ramnarine,Varune Rohan Ramnarine,Varune Rohan Ramnarine,CQ Yao,CQ Yao,Chad A. Malloff,Lucia L. Lam,Honglei Xie,Nicholas J. Harding,Denise Y.F. Mak,Kenneth C. Chu,Kenneth C. Chu,Lauren C. Chong,Dorota H. Sendorek,Christine P'ng,Colin Collins,Jeremy A. Squire,Igor Jurisica,Igor Jurisica,Colin Cooper,Colin Cooper,Rosalind A. Eeles,Rosalind A. Eeles,Melania Pintilie,Alan Dal Pra,Alan Dal Pra,Alan Dal Pra,Elai Davicioni,Wan L. Lam,Michael Milosevic,David E. Neal,Theodorus van der Kwast,Theodorus van der Kwast,Paul C. Boutros,Robert G. Bristow,Robert G. Bristow +57 more
TL;DR: This is the first study of cancer outcome to integrate DNA-based and microenvironment-based failure indices to predict patient outcome and identifies low-risk to high-risk patients who are most likely to fail treatment within 18 months.
Journal ArticleDOI
Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology
Neal I. Lindeman,Philip T. Cagle,Mary Beth Beasley,Dhananjay Chitale,Sanja Dacic,Giuseppe Giaccone,Robert Brian Jenkins,David J. Kwiatkowski,Juan Sebastian Saldivar,Jeremy A. Squire,Erik Thunnissen,Marc Ladanyi +11 more
TL;DR: The major recommendations are to use testing for EGFR mutations and ALK fusions to guide patient selection for therapy with an epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) inhibitor, respectively, in all patients with advanced-stage adenocarcinoma.